MA49771A - Induction d'une immunité protectrice contre des antigènes - Google Patents
Induction d'une immunité protectrice contre des antigènesInfo
- Publication number
- MA49771A MA49771A MA049771A MA49771A MA49771A MA 49771 A MA49771 A MA 49771A MA 049771 A MA049771 A MA 049771A MA 49771 A MA49771 A MA 49771A MA 49771 A MA49771 A MA 49771A
- Authority
- MA
- Morocco
- Prior art keywords
- induction
- immunity against
- protective immunity
- against antigens
- antigens
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 230000036039 immunity Effects 0.000 title 1
- 230000006698 induction Effects 0.000 title 1
- 230000001681 protective effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541293P | 2017-08-04 | 2017-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49771A true MA49771A (fr) | 2020-06-10 |
Family
ID=65233106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049771A MA49771A (fr) | 2017-08-04 | 2018-08-03 | Induction d'une immunité protectrice contre des antigènes |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11596677B2 (fr) |
| EP (1) | EP3661547A4 (fr) |
| CN (1) | CN111182920B (fr) |
| BR (1) | BR112020002374A2 (fr) |
| MA (1) | MA49771A (fr) |
| WO (1) | WO2019028396A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7121016B2 (ja) | 2017-01-23 | 2022-08-17 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド | 抗原に対する防御免疫の誘導 |
| WO2022140640A1 (fr) * | 2020-12-23 | 2022-06-30 | Chan Zuckerberg Biohub, Inc. | Bactéries modifiées pour engendrer des lymphocytes t spécifiques à un antigène |
| EP4332228A4 (fr) * | 2021-04-30 | 2024-09-11 | Industry Foundation of Chonnam National University | Souche atténuée de salmonella gallinarum et son utilisation |
| CN116287084A (zh) * | 2022-11-28 | 2023-06-23 | 广东筑美生物医疗科技有限公司 | 一种酶转化合成脱氧胆酸的方法 |
| CN117737001B (zh) * | 2022-12-27 | 2024-08-09 | 菲吉乐科(南京)生物科技有限公司 | 一种防治犬细菌性腹泻的大肠杆菌噬菌体及其应用 |
| CN120737153A (zh) * | 2023-11-01 | 2025-10-03 | 东南大学 | 一种靶向cldn4蛋白的多肽及其制备方法和应用 |
| CN119192395B (zh) * | 2024-09-20 | 2025-03-14 | 中国动物卫生与流行病学中心 | 一种抗禽产气荚膜梭菌的亚单位疫苗 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY149604A (en) * | 2005-04-18 | 2013-09-13 | Schering Plough Ltd | C.perfringens alpha toxoid vaccine |
| EP2162150A4 (fr) | 2007-06-22 | 2011-10-12 | Univ Guelph | Vaccin contre le clostridium perfringens |
| WO2009046449A1 (fr) | 2007-10-05 | 2009-04-09 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Bactéries recombinantes capables de susciter une réponse immunitaire contre des agents pathogènes entériques |
| WO2010045620A1 (fr) | 2008-10-17 | 2010-04-22 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Bactérie recombinante pouvant éliciter une réponse immunitaire contre le streptococcus pneumoniae |
| US9598697B2 (en) * | 2010-05-28 | 2017-03-21 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium to decrease tumor growth |
| US9198950B2 (en) * | 2010-11-24 | 2015-12-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Recombinant bacterium comprising a toxin/antitoxin system |
| EP2834356A4 (fr) | 2012-04-02 | 2015-09-02 | Univ Arizona | Bactérie recombinante pour induire une réponse immunitaire cellulaire |
| US10238695B2 (en) | 2012-11-30 | 2019-03-26 | Universite D'auvergne Clermont I | Use of microorganisms for reducing the level of trimethylamine in a human body cavity, in particular for the treatment of trimethylaminuria or of bacterial vaginosis and the prevention of cardiovascular diseases |
| WO2015118541A1 (fr) | 2014-02-05 | 2015-08-13 | Gavish-Galilee Bio Applications Ltd | Système génétique pour générer des bactéries inactivées ou atténuées de manière conditionnelle |
| WO2018018041A1 (fr) | 2016-07-22 | 2018-01-25 | University Of Florida Research Foundation, Incorporated | Conception d'un vaccin anti-zikv qui n'a pas de réaction croisées avec la dengue. |
| JP7121016B2 (ja) | 2017-01-23 | 2022-08-17 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド | 抗原に対する防御免疫の誘導 |
-
2018
- 2018-08-03 US US16/636,251 patent/US11596677B2/en active Active
- 2018-08-03 MA MA049771A patent/MA49771A/fr unknown
- 2018-08-03 BR BR112020002374-4A patent/BR112020002374A2/pt unknown
- 2018-08-03 CN CN201880065105.1A patent/CN111182920B/zh active Active
- 2018-08-03 WO PCT/US2018/045231 patent/WO2019028396A1/fr not_active Ceased
- 2018-08-03 EP EP18841409.8A patent/EP3661547A4/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3661547A1 (fr) | 2020-06-10 |
| WO2019028396A1 (fr) | 2019-02-07 |
| CN111182920B (zh) | 2023-09-12 |
| BR112020002374A2 (pt) | 2020-09-08 |
| CN111182920A (zh) | 2020-05-19 |
| US20200368339A1 (en) | 2020-11-26 |
| EP3661547A4 (fr) | 2021-06-09 |
| WO2019028396A8 (fr) | 2020-02-13 |
| US11596677B2 (en) | 2023-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49771A (fr) | Induction d'une immunité protectrice contre des antigènes | |
| MA47317A (fr) | Induction d'immunité protectrice contre des antigènes | |
| EP3507298A4 (fr) | Détection d'un carcinome hépatocellulaire | |
| EP3362472A4 (fr) | Compositions et méthodes d'inhibition d'antigènes spécifiques à une lignée | |
| EP3303083A4 (fr) | Réduction des risques d'itinéraire | |
| EP3526328A4 (fr) | Polythérapie pour l'inhibition de c3 | |
| MA49715A (fr) | Oligomères et conjugués d'oligomères | |
| EP3419674A4 (fr) | Immunothérapie de ciblage de l'amyloïdose | |
| EP3415146A4 (fr) | Inhibiteur de l'activation des inflammasomes | |
| MA43378A (fr) | Compositions et méthodes pour la reduction de la réponse immunitaire contre récepteurs d'antigène chimériques | |
| DK3410822T3 (da) | Elektromagnetisk induktionsopvarmer | |
| EP3478315A4 (fr) | Méthodes et compositions d'inhibition du récepteur immunitaire inhibiteur | |
| EP3347334A4 (fr) | Déshydrohalogénation d'hydrochlorofluorocarbones | |
| EP3661552A4 (fr) | Compositions et méthodes d'inhibition de l'élimination de mica/b | |
| EP3533253A4 (fr) | Régulation d'encombrement 5g | |
| BE1022355A1 (fr) | Nouvelles méthodes d'induction d'une réponse immunitaire | |
| EP3403094A4 (fr) | Bilbiothèque des produits d'addition ligand d'arn de transfert | |
| ITUB20153017A1 (it) | Dispositivo per l'avvolgimento di prodotti | |
| EP3345618A4 (fr) | AGENT DESTINÉ À AMÉLIORER L'IMMUNITÉ CONTRE LE CANCER EMPLOYANT UN ANTAGONISTE D'Allergine-1 | |
| MA43764A (fr) | Inhibiteur monovalent de l'interaction hutnfr1 | |
| EP3335725A4 (fr) | Inducteur de la réponse immunitaire | |
| EP3781195A4 (fr) | Antigènes vaccinaux chimériques contre l'anaplasmose | |
| DK3535461T3 (da) | Sprængningsbeskyttelsesvæg | |
| EP3387469A4 (fr) | Détermination d'électrofaciès | |
| EP3697947A4 (fr) | Prise en compte d'effets d'ajustement induit |